Meta Agrees to $18 Billion Settlement, Tightens Teen Social Media Rules 
Mercer International Stock Surges 45% on C$20 Million Canada Funding 
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation 
Salesforce Shares Surge as AI Demand Powers Q2 Earnings Beat 
Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14% 
Itochu Offers $1.56 Billion to Privatize Dentsu Soken 
Toyota Global Sales Fall as China Demand Slumps 
HP Stock Drops 9% Despite Q3 Earnings Beat and Raised 2026 Outlook 
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China 
Google Changes EU Spam Policy Amid Antitrust Scrutiny 
Nvidia Pauses AI Cloud Financing Deals Amid Antitrust Concerns 
Honda, Nissan Eye Shared Vehicle Software Platform by 2029 
CIA-Linked Investor Helped Quantum Systems Expand in US 
Street Poller Media and The Boom of the Street Interview Ad Industry 
BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake 
OpenAI AI Agent Swarm Behind Hugging Face Hack 
Jefferies Names AMEC Top China Semiconductor Equipment Pick 
Add as a preferred source on Google
AMES, Iowa, April 03, 2018 -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today it will present at the H. C. Wainwright Annual Global Life Sciences Conference. The conference is being held on April 8-10 at the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco.
NewLink Genetics management will participate in a fireside chat Tuesday, April 10, 2018, entitled “Advances of Immuno-oncology” 8:00 AM – 9:00 AM CET. In addition, management will provide an overview of the Company's business during a live presentation April 10th, 1:20 PM – 1:45PM CET, and will be available for one-on-one meetings with investors who are registered to attend the conference.
If you are an institutional investor, and would like to attend the Company’s presentation, please click on the following link (www.hcwevents.com) to register for the conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.
A live webcast of the conference presentation will be available on the Company’s website at www.newlinkgenetics.com in the “Investors & Media” section under “Events & Presentations.”
About NewLink Genetics Corporation
NewLink Genetics is a late-stage biopharmaceutical company focusing on discovering, developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer. NewLink Genetics' IDO pathway inhibitors are designed to harness multiple components of the immune system to combat cancer. For more information, please visit www.newlinkgenetics.com and follow us on Twitter @NLNKGenetics.
Investor Contact:
Lisa Miller
Director of Investor Relations
NewLink Genetics
515-598-2555
[email protected]
Media Contact:
Sharon Correia
VP, Integrated Communications
LaVoieHealthScience
617-374-8800, ext. 105
[email protected]
